Eckert & Ziegler BEBIG S.A. Executes Framework Agreement with Leading Russian Radiation Therapy Provider

Berlin, January 07, 2013 - Eckert & Ziegler BEBIG S.A., an associated company of Eckert & Ziegler AG (ISIN DE0005659700), announces the signing of a framework agreement for the local production of brachytherapy devices with ZAO MSM-Medimpex (hereafter "MSM"), a leading Russian distributor of radiation therapy and nuclear medicine equipment. The contract covers the sale of production assets from BEBIG to MSM, a license for the use of BEBIG know-how, and support for the development of local afterloader modules. The agreement will enable MSM to manufacture a line of Russian brachytherapy devices for the precise treatment of cancer.

"The agreement will bring MSM and BEBIG closer together and thereby strengthen BEBIG's position in the Russian brachytherapy market", explains Dr. Edgar Löffler, Managing Director at Eckert & Ziegler BEBIG. "It allows BEBIG to participate more prominently in future Russian government cancer care investments, which are expected to increase significantly under the new State Oncology Program. Over the last years, BEBIG has already sold over 70 temporary brachytherapy systems. There is still an enormous potential for the use of such equipment in Russia. Together with MSM we are determined to exploit it. The revenues generated by this contract will reach well over 30 million EUR for both parties over the following three years."
 
"MSM is proud to announce this result of our long-term fruitful collaboration with Eckert & Ziegler BEBIG in the field of temporary brachytherapy," says Andrey Popov, Director General of MSM. "We have built a strong market presence with the BEBIG cancer therapy equipment over the last years due to the unique temporary brachytherapy devices with miniaturized Co-60 sources. Also, this contract allows us to participate on the Federal Target Program. The local production will give us a significant advantage over our competitors in upcoming government tenders."

With more than 600 employees the Eckert & Ziegler Group belongs to the largest providers of isotope components for radiotherapy and nuclear medicine worldwide.

If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de